;PMID: 11549104
;source_file_984.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..146] = [t:46..146]
;2)section:[e:150..248] = [t:150..248]
;3)section:[e:252..331] = [t:252..331]
;4)sentence:[e:335..487] = [t:335..487]
;5)sentence:[e:489..602] = [t:489..602]
;6)sentence:[e:603..733] = [t:603..733]
;7)sentence:[e:734..823] = [t:734..823]
;8)sentence:[e:824..1224] = [t:824..1224]
;9)sentence:[e:1225..1305] = [t:1225..1305]
;10)sentence:[e:1306..1525] = [t:1306..1525]
;11)sentence:[e:1526..1874] = [t:1526..1874]
;12)section:[e:1875..2023] = [t:1875..2023]
;13)section:[e:2027..2045] = [t:2027..2045]
;14)section:[e:2051..2065] = [t:2051..2065]
;15)section:[e:2071..2098] = [t:2071..2098]
;16)section:[e:2102..2147] = [t:2102..2147]

;section 0 Span:0..40
;J Clin Pharmacol. 2001 Sep;41(9):987-93.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..16] Pharmacol) (.:[16..17] .)
        (CD:[18..22] 2001) (CC:[23..30] Sep;41-LRB-) (CD:[30..31] 9)
        (-RRB-:[31..32] -RRB-) (CD:[32..36] :987) (IN:[36..37] -)
        (CD:[37..39] 93) (.:[39..40] .)))

;sentence 1 Span:46..146
;Tegaserod coadministration does not alter the pharmacokinetics of
;theophylline  in healthy subjects.
;[46..55]:substance:"Tegaserod"
;[112..124]:substance:"theophylline"
(SENT
  (S-HLN
    (NP-SBJ (NN:[46..55] Tegaserod) (NN:[56..72] coadministration))
    (VP (VBZ:[73..77] does) (RB:[78..81] not)
      (VP (VB:[82..87] alter)
        (NP
          (NP (DT:[88..91] the) (NNS:[92..108] pharmacokinetics))
          (PP (IN:[109..111] of)
            (NP (NN:[112..124] theophylline))))
        (PP-LOC (IN:[126..128] in)
          (NP (JJ:[129..136] healthy) (NNS:[137..145] subjects)))))
    (.:[145..146] .)))

;section 2 Span:150..248
;Zhou H, Khalilieh S, Svendsen K, Pommier F, Osborne S, Appel-Dingemanse S, 
;Lasseter K, McLeod JF.
(SEC
  (FRAG (NNP:[150..154] Zhou) (NNP:[155..156] H) (,:[156..157] ,)
        (NNP:[158..167] Khalilieh) (NNP:[168..170] S,) (NNP:[171..179] Svendsen)
        (NNP:[180..181] K) (NNP:[181..182] ,) (NNP:[183..190] Pommier)
        (NNP:[191..192] F) (,:[192..193] ,) (DT:[194..201] Osborne)
        (NNP:[202..204] S,) (NNP:[205..210] Appel) (HYPH:[210..211] -)
        (NNP:[211..221] Dingemanse) (NNP:[222..224] S,)
        (NNP:[226..234] Lasseter) (NNP:[235..236] K) (,:[236..237] ,)
        (NNP:[238..244] McLeod) (NNP:[245..248] JF.)))

;section 3 Span:252..331
;Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936-1080,
;USA.
(SEC
  (FRAG (NNP:[252..260] Novartis) (NNP:[261..276] Pharmaceuticals)
        (NNP:[277..288] Corporation) (,:[288..289] ,) (NNP:[290..294] East)
        (NNP:[295..302] Hanover) (,:[302..303] ,) (NNP:[304..307] New)
        (NNP:[308..314] Jersey) (CD:[315..320] 07936) (HYPH:[320..321] -)
        (CD:[321..325] 1080) (,:[325..326] ,) (NNP:[327..330] USA)
        (.:[330..331] .)))

;sentence 4 Span:335..487
;Tegaserod (HTF 919), a selective 5-HT4 receptor partial agonist, is in 
;development for the treatment of functional gastrointestinal motility
;disorders.
;[335..344]:substance:"Tegaserod"
;[346..353]:substance:"HTF 919"
;[368..382]:substance:"5-HT4 receptor"
;[391..398]:substance:"agonist"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[335..344] Tegaserod))
        (NP (-LRB-:[345..346] -LRB-)
           (NN:[346..349] HTF) (CD:[350..353] 919)
          (-RRB-:[353..354] -RRB-)))
      (,:[354..355] ,)
      (NP (DT:[356..357] a) (JJ:[358..367] selective)
         (NN:[368..373] 5-HT4) (NN:[374..382] receptor)
        (JJ:[383..390] partial) (NN:[391..398] agonist)))
    (,:[398..399] ,)
    (VP (VBZ:[400..402] is)
      (PP-PRD (IN:[403..405] in)
        (NP
          (NP (NN:[407..418] development))
          (PP (IN:[419..422] for)
            (NP
              (NP (DT:[423..426] the) (NN:[427..436] treatment))
              (PP (IN:[437..439] of)
                (NP (JJ:[440..450] functional) (JJ:[451..467] gastrointestinal)
                    (NN:[468..476] motility) (NNS:[477..486] disorders))))))))
    (.:[486..487] .)))

;sentence 5 Span:489..602
;Tegaserod has been found to inhibit cytochrome P-450 (CYP) 1A2, for which 
;theophylline is a prototype substrate.
;[489..498]:substance:"Tegaserod"
;[525..551]:cyp450:"cytochrome P-450 (CYP) 1A2"
;[564..576]:substance:"theophylline"
;[592..601]:substance:"substrate"
(SENT
  (S
    (NP-SBJ-2 (NN:[489..498] Tegaserod))
    (VP (VBZ:[499..502] has)
      (VP (VBN:[503..507] been)
        (VP (VBN:[508..513] found)
          (S
            (NP-SBJ-2 (-NONE-:[513..513] *))
            (VP (TO:[514..516] to)
              (VP (VB:[517..524] inhibit)
                (NP
                  (NP
                    (NML (NN:[525..535] cytochrome) (NN:[536..541] P-450))
                    (NML (-LRB-:[542..543] -LRB-) (NN:[543..546] CYP)
                         (-RRB-:[546..547] -RRB-))
                    (NN:[548..551] 1A2))
                  (,:[551..552] ,)
                  (SBAR
                    (WHPP-1 (IN:[553..556] for)
                      (WHNP (WDT:[557..562] which)))
                    (S
                      (NP-SBJ (NN:[564..576] theophylline))
                      (VP (VBZ:[577..579] is)
                        (NP-PRD (DT:[580..581] a) (NN:[582..591] prototype)
                                (NN:[592..601] substrate))
                        (PP-1 (-NONE-:[601..601] *T*))))))))))))
    (.:[601..602] .)))

;sentence 6 Span:603..733
;This study was designed to assess the  effect of tegaserod on the single-dose
;pharmacokinetic and safety profile of  theophylline.
;[652..661]:substance:"tegaserod"
;[720..732]:substance:"theophylline"
(SENT
  (S
    (NP-SBJ-3 (DT:[603..607] This) (NN:[608..613] study))
    (VP (VBD:[614..617] was)
      (VP (VBN:[618..626] designed)
        (NP-3 (-NONE-:[626..626] *))
        (S-PRP
          (NP-SBJ (-NONE-:[626..626] *))
          (VP (TO:[627..629] to)
            (VP (VB:[630..636] assess)
              (NP
                (NP (DT:[637..640] the) (NN:[642..648] effect))
                (PP (IN:[649..651] of)
                  (NP (NN:[652..661] tegaserod))))
              (PP (IN:[662..664] on)
                (NP
                  (NP (DT:[665..668] the)
                    (NML
                      (NML
                        (NML-2 (JJ:[669..675] single) (HYPH:[675..676] -)
                               (NN:[676..680] dose))
                        (JJ:[681..696] pharmacokinetic)
                        (NML-1 (-NONE-:[696..696] *P*)))
                      (CC:[697..700] and)
                      (NML
                        (NML-2 (-NONE-:[700..700] *P*))
                        (NN:[701..707] safety)
                        (NML-1 (NN:[708..715] profile)))))
                  (PP (IN:[716..718] of)
                    (NP (NN:[720..732] theophylline))))))))))
    (.:[732..733] .)))

;sentence 7 Span:734..823
;Eighteen subjects were enrolled in a randomized, open-label,  two-period
;crossover study.
(SENT
  (S
    (NP-SBJ-1 (CD:[734..742] Eighteen) (NNS:[743..751] subjects))
    (VP (VBD:[752..756] were)
      (VP (VBN:[757..765] enrolled)
        (NP-1 (-NONE-:[765..765] *))
        (PP (IN:[766..768] in)
          (NP (DT:[769..770] a) (VBN:[771..781] randomized) (,:[781..782] ,)
            (NML (JJ:[783..787] open) (HYPH:[787..788] -) (NN:[788..793] label))
            (,:[793..794] ,)
            (NML (CD:[796..799] two) (HYPH:[799..800] -) (NN:[800..806] period))
            (NN:[807..816] crossover) (NN:[817..822] study)))))
    (.:[822..823] .)))

;sentence 8 Span:824..1224
;After an overnight fast, subjects were randomized to  receive one of two
;treatments: (1) a single dose of controlled-release  formulation of
;theophylline (Theo-Dur, 600 mg) on day 1 or (2) a single dose of  tegaserod
;(6 mg) on day 1, concomitant administration of tegaserod (6 mg) and 
;theophylline (600 mg) on the morning of day 2, followed by an additional dose
;of  tegaserod (6 mg) 12 hours later.
;[965..977]:substance:"theophylline"
;[979..987]:substance:"Theo-Dur"
;[989..992]:quantitative-value:"600"
;[993..995]:quantitative-units:"mg"
;[1031..1040]:substance:"tegaserod"
;[1042..1043]:quantitative-value:"6"
;[1044..1046]:quantitative-units:"mg"
;[1088..1097]:substance:"tegaserod"
;[1099..1100]:quantitative-value:"6"
;[1101..1103]:quantitative-units:"mg"
;[1110..1122]:substance:"theophylline"
;[1124..1127]:quantitative-value:"600"
;[1128..1130]:quantitative-units:"mg"
;[1192..1201]:substance:"tegaserod"
;[1203..1204]:quantitative-value:"6"
;[1205..1207]:quantitative-units:"mg"
(SENT
  (S
    (PP-TMP (IN:[824..829] After)
      (NP (DT:[830..832] an) (JJ:[833..842] overnight) (NN:[843..847] fast)))
    (,:[847..848] ,)
    (NP-SBJ-1 (NNS:[849..857] subjects))
    (VP (VBD:[858..862] were)
      (VP (VBN:[863..873] randomized)
        (NP-1 (-NONE-:[873..873] *))
        (S-ADV
          (NP-SBJ (-NONE-:[873..873] *))
          (VP (TO:[874..876] to)
            (VP (VB:[878..885] receive)
              (NP
                (NP (CD:[886..889] one))
                (PP (IN:[890..892] of)
                  (NP
                    (NP (CD:[893..896] two) (NNS:[897..907] treatments))
                    (::[907..908] :)
                    (NP
                      (NP
                        (LST (LS:[909..912] -LRB-1-RRB-))
                        (NP (DT:[913..914] a) (JJ:[915..921] single)
                            (NN:[922..926] dose))
                        (PP (IN:[927..929] of)
                          (NP
                            (NP
                              (NML (VBN:[930..940] controlled)
                                   (HYPH:[940..941] -) (NN:[941..948] release))
                              (NN:[950..961] formulation))
                            (PP (IN:[962..964] of)
                              (NP (NN:[965..977] theophylline)
                                (PRN (-LRB-:[978..979] -LRB-)
                                  (NP (NNP:[979..983] Theo) (HYPH:[983..984] -)
                                      (NNP:[984..987] Dur))
                                  (,:[987..988] ,)
                                  (NP (CD:[989..992] 600) (NN:[993..995] mg))
                                  (-RRB-:[995..996] -RRB-))))))
                        (PP-TMP (IN:[997..999] on)
                          (NP (NN:[1000..1003] day) (CD:[1004..1005] 1))))
                      (CC:[1006..1008] or)
                      (NP
                        (LST (LS:[1009..1012] -LRB-2-RRB-))
                        (NP
                          (NP (DT:[1013..1014] a) (JJ:[1015..1021] single)
                              (NN:[1022..1026] dose))
                          (PP (IN:[1027..1029] of)
                            (NP (NN:[1031..1040] tegaserod)))
                          (PRN (-LRB-:[1041..1042] -LRB-)
                            (NP (CD:[1042..1043] 6) (NN:[1044..1046] mg))
                            (-RRB-:[1046..1047] -RRB-))
                          (PP-TMP (IN:[1048..1050] on)
                            (NP (NN:[1051..1054] day) (CD:[1055..1056] 1))))
                        (,:[1056..1057] ,)
                        (NP
                          (NP
                            (NP (JJ:[1058..1069] concomitant)
                                (NN:[1070..1084] administration))
                            (PP (IN:[1085..1087] of)
                              (NP
                                (NP (NN:[1088..1097] tegaserod)
                                  (PRN (-LRB-:[1098..1099] -LRB-)
                                    (NP (CD:[1099..1100] 6) (NN:[1101..1103] mg))
                                    (-RRB-:[1103..1104] -RRB-)))
                                (CC:[1105..1108] and)
                                (NP (NN:[1110..1122] theophylline)
                                  (PRN (-LRB-:[1123..1124] -LRB-)
                                    (NP (CD:[1124..1127] 600)
                                        (NN:[1128..1130] mg))
                                    (VBD:[1130..1131] -RRB-)))))
                            (PP-TMP (IN:[1132..1134] on)
                              (NP
                                (NP (DT:[1135..1138] the)
                                    (NN:[1139..1146] morning))
                                (PP (IN:[1147..1149] of)
                                  (NP (NN:[1150..1153] day) (CD:[1154..1155] 2))))))
                          (,:[1155..1156] ,)
                          (VP (VBN:[1157..1165] followed)
                            (NP (-NONE-:[1165..1165] *))
                            (PP (IN:[1166..1168] by)
                              (NP-LGS
                                (NP (DT:[1169..1171] an)
                                    (JJ:[1172..1182] additional)
                                    (NN:[1183..1187] dose))
                                (PP (IN:[1188..1190] of)
                                  (NP (NN:[1192..1201] tegaserod)))
                                (PRN (-LRB-:[1202..1203] -LRB-)
                                  (NP (CD:[1203..1204] 6) (NN:[1205..1207] mg))
                                  (-RRB-:[1207..1208] -RRB-))))
                            (ADVP-TMP
                              (NP-ADV (CD:[1209..1211] 12)
                                      (NNS:[1212..1217] hours))
                              (RB:[1218..1223] later))))))))))))))
    (.:[1223..1224] .)))

;sentence 9 Span:1225..1305
;Four to 10 days later, the subjects received  the alternative treatment
;regimen.
;[1225..1235]:quantitative-value:"Four to 10"
;[1236..1240]:quantitative-units:"days"
(SENT
  (S
    (ADVP-TMP
      (NP
        (QP (CD:[1225..1229] Four) (TO:[1230..1232] to) (CD:[1233..1235] 10))
        (NNS:[1236..1240] days))
      (RB:[1241..1246] later))
    (,:[1246..1247] ,)
    (NP-SBJ (DT:[1248..1251] the) (NNS:[1252..1260] subjects))
    (VP (VBD:[1261..1269] received)
      (NP (DT:[1271..1274] the) (JJ:[1275..1286] alternative)
          (NN:[1287..1296] treatment) (NN:[1297..1304] regimen)))
    (.:[1304..1305] .)))

;sentence 10 Span:1306..1525
;The pharmacokinetic parameters of  theophylline, including AUC, Cmax, and
;t(1/2lambda z), were similar for both  treatment regimens, although the tmax
;of theophylline was statistically  different between the treatments.
;[1341..1353]:substance:"theophylline"
;[1365..1368]:quantitative-name:"AUC"
;[1370..1374]:quantitative-name:"Cmax"
;[1380..1394]:quantitative-name:"t(1/2lambda z)"
;[1452..1456]:quantitative-name:"tmax"
;[1460..1472]:substance:"theophylline"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1306..1309] The) (JJ:[1310..1325] pharmacokinetic)
          (NNS:[1326..1336] parameters))
      (PP (IN:[1337..1339] of)
        (NP (NN:[1341..1353] theophylline)))
      (,:[1353..1354] ,)
      (PP (VBG:[1355..1364] including)
        (NP
          (NP (NN:[1365..1368] AUC))
          (,:[1368..1369] ,)
          (NP (NN:[1370..1374] Cmax))
          (,:[1374..1375] ,) (CC:[1376..1379] and)
          (NP (NN:[1380..1381] t) (-LRB-:[1381..1382] -LRB-) (CD:[1382..1383] 1)
              (SYM:[1383..1384] /) (CD:[1384..1385] 2) (SYM:[1385..1391] lambda)
              (NN:[1392..1393] z) (-RRB-:[1393..1394] -RRB-)))))
    (,:[1394..1395] ,)
    (VP (VBD:[1396..1400] were)
      (ADJP-PRD (JJ:[1401..1408] similar))
      (PP (IN:[1409..1412] for)
        (NP (DT:[1413..1417] both) (NN:[1419..1428] treatment)
            (NNS:[1429..1437] regimens)))
      (,:[1437..1438] ,)
      (SBAR-ADV (IN:[1439..1447] although)
        (S
          (NP-SBJ
            (NP (DT:[1448..1451] the) (NN:[1452..1456] tmax))
            (PP (IN:[1457..1459] of)
              (NP (NN:[1460..1472] theophylline))))
          (VP (VBD:[1473..1476] was)
            (ADVP (RB:[1477..1490] statistically))
            (ADJP-PRD (JJ:[1492..1501] different))
            (PP (IN:[1502..1509] between)
              (NP (DT:[1510..1513] the) (NNS:[1514..1524] treatments)))))))
    (.:[1524..1525] .)))

;sentence 11 Span:1526..1874
;Except for a decrease in partial metabolic  formation clearance from
;theophylline to 1-methyluric acid, which is unlikely to  be clinically
;relevant, there were no statistically significant differences in  renal
;clearance of theophylline and partial metabolic formation clearances 
;following the combined treatment compared with theophylline alone.
;[1595..1607]:substance:"theophylline"
;[1611..1628]:substance:"1-methyluric acid"
;[1751..1763]:substance:"theophylline"
;[1855..1867]:substance:"theophylline"
(SENT
  (S
    (PP (IN:[1526..1532] Except)
      (PP (IN:[1533..1536] for)
        (NP
          (NP
            (NP (DT:[1537..1538] a) (NN:[1539..1547] decrease))
            (PP (IN:[1548..1550] in)
              (NP
                (NP (JJ:[1551..1558] partial) (JJ:[1559..1568] metabolic)
                    (NN:[1570..1579] formation) (NN:[1580..1589] clearance))
                (PP (IN:[1590..1594] from)
                  (NP
                    (NP (NN:[1595..1607] theophylline))
                    (PP (TO:[1608..1610] to)
                      (NP (JJ:[1611..1623] 1-methyluric) (NN:[1624..1628] acid))))))))
          (,:[1628..1629] ,)
          (SBAR
            (WHNP-1 (WDT:[1630..1635] which))
            (S
              (NP-SBJ-1 (-NONE-:[1635..1635] *T*))
              (VP (VBZ:[1636..1638] is)
                (ADJP-PRD (JJ:[1639..1647] unlikely)
                  (S
                    (NP-SBJ-1 (-NONE-:[1647..1647] *))
                    (VP (TO:[1648..1650] to)
                      (VP (VB:[1652..1654] be)
                        (ADJP-PRD (RB:[1655..1665] clinically)
                                  (JJ:[1666..1674] relevant))))))))))))
    (,:[1674..1675] ,)
    (NP-SBJ (EX:[1676..1681] there))
    (VP (VBD:[1682..1686] were)
      (NP-PRD
        (NP (DT:[1687..1689] no)
          (ADJP (RB:[1690..1703] statistically) (JJ:[1704..1715] significant))
          (NNS:[1716..1727] differences))
        (PP (IN:[1728..1730] in)
          (NP
            (NP
              (NP (JJ:[1732..1737] renal) (NN:[1738..1747] clearance))
              (PP (IN:[1748..1750] of)
                (NP (NN:[1751..1763] theophylline))))
            (CC:[1764..1767] and)
            (NP (JJ:[1768..1775] partial) (JJ:[1776..1785] metabolic)
                (NN:[1786..1795] formation) (NNS:[1796..1806] clearances))))
        (VP (VBG:[1808..1817] following)
          (NP (DT:[1818..1821] the) (VBN:[1822..1830] combined)
              (NN:[1831..1840] treatment))))
      (S-ADV
        (NP-SBJ-2 (-NONE-:[1840..1840] *))
        (VP (VBN:[1841..1849] compared)
          (NP-SBJ-2 (-NONE-:[1849..1849] *))
          (PP (IN:[1850..1854] with)
            (NP
              (NP (NN:[1855..1867] theophylline))
              (ADVP (RB:[1868..1873] alone)))))))
    (.:[1873..1874] .)))

;section 12 Span:1875..2023
;The results  of the current study indicate that no dose adjustment is
;required when drugs  metabolized via CYP1A2 are coadministered with
;tegaserod.
;[1959..1964]:substance:"drugs"
;[1982..1988]:cyp450:"CYP1A2"
;[2013..2022]:substance:"tegaserod"
(SEC
  (S
    (NP-SBJ
      (NP (DT:[1875..1878] The) (NNS:[1879..1886] results))
      (PP (IN:[1888..1890] of)
        (NP (DT:[1891..1894] the) (JJ:[1895..1902] current)
            (NN:[1903..1908] study))))
    (VP (VBP:[1909..1917] indicate)
      (SBAR (IN:[1918..1922] that)
        (S
          (NP-SBJ-3 (DT:[1923..1925] no) (NN:[1926..1930] dose)
                    (NN:[1931..1941] adjustment))
          (VP (VBZ:[1942..1944] is)
            (VP (VBN:[1945..1953] required)
              (NP-3 (-NONE-:[1953..1953] *))
              (SBAR-ADV
                (WHADVP-2 (WRB:[1954..1958] when))
                (S
                  (NP-SBJ-1
                    (NP (NNS:[1959..1964] drugs))
                    (VP (VBN:[1966..1977] metabolized)
                      (NP (-NONE-:[1977..1977] *))
                      (PP (IN:[1978..1981] via)
                        (NP (NN:[1982..1988] CYP1A2)))))
                  (VP (VBP:[1989..1992] are)
                    (VP (VBN:[1993..2007] coadministered)
                      (NP-1 (-NONE-:[2007..2007] *))
                      (PP (IN:[2008..2012] with)
                        (NP (NN:[2013..2022] tegaserod)))
                      (ADVP-2 (-NONE-:[2022..2022] *T*)))))))))))
    (.:[2022..2023] .)))
;ERROR_Entity in section[1959..1964]:substance "drugs"
;ERROR_Entity in section[1982..1988]:cyp450 "CYP1A2"
;ERROR_Entity in section[2013..2022]:substance "tegaserod"

;section 13 Span:2027..2045
;Publication Types:
(SEC
  (FRAG (NNP:[2027..2038] Publication) (NNP:[2039..2044] Types)
        (::[2044..2045] :)))

;section 14 Span:2051..2065
;Clinical Trial
(SEC
  (FRAG (NNP:[2051..2059] Clinical) (NNP:[2060..2065] Trial)))

;section 15 Span:2071..2098
;Randomized Controlled Trial
(SEC
  (FRAG (NNP:[2071..2081] Randomized) (NNP:[2082..2092] Controlled)
        (NNP:[2093..2098] Trial)))

;section 16 Span:2102..2147
;PMID: 11549104 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2102..2106] PMID) (::[2106..2107] :) (CD:[2108..2116] 11549104)
        (IN:[2117..2118] -LSB-) (NNP:[2118..2124] PubMed) (HYPH:[2125..2126] -)
        (JJ:[2127..2134] indexed) (IN:[2135..2138] for)
        (NNP:[2139..2147] MEDLINE-RSB-)))
